John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
Douglas Elliman
DOUG
$177M
| $344K | ﹤0.01% |
49,513
-25,456
| -34% | -$193K |
|
|
ATIP
2152
DELISTED
ATI Physical Therapy, Inc.
ATIP
| $344K | ﹤0.01% |
+3,659
| New | +$466K |
|
|
CALA
2153
DELISTED
Calithera Biosciences, Inc
CALA
| $342K | ﹤0.01% |
42,274
-6,887
| -14% | -$70.4K |
|
2154
Rayonier Advanced Materials
RYAM
$582M
| $341K | ﹤0.01% |
51,911
+28,049
| +118% | +$171K |
|
|
VINC
2155
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $341K | ﹤0.01% |
4,261
+3,092
| +264% | +$382K |
|
|
VBIV
2156
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $341K | ﹤0.01% |
6,843
+2,870
| +72% | +$142K |
|
2157
Park Aerospace
PKE
$707M
| $340K | ﹤0.01% |
26,022
-185
| -0.7% | -$2.48K |
|
|
ACR
2158
ACRES Commercial Realty
ACR
$106M
| $339K | ﹤0.01% |
25,283
-35,192
| -58% | -$434K |
|
2159
Chesapeake Utilities
CPK
$3.25B
| $339K | ﹤0.01% |
+2,460
| New | +$331K |
|
|
KDNY
2160
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $335K | ﹤0.01% |
20,482
-191,110
| -90% | -$2.6M |
|
2161
Red River Bancshares
RRBI
$663M
| $334K | ﹤0.01% |
6,318
-359
| -5% | -$18.6K |
|
2162
Noodles & Co
NDLS
$92.5M
| $333K | ﹤0.01% |
6,965
-11,029
| -61% | -$677K |
|
2163
Northwest Bancshares
NWBI
$2.24B
| $333K | ﹤0.01% |
24,658
-21,565
| -47% | -$304K |
|
2164
Immuneering
IMRX
$338M
| $332K | ﹤0.01% |
+51,360
| New | +$493K |
|
|
KNDI
2165
Kandi Technologies Group
KNDI
$66.3M
| $330K | ﹤0.01% |
+103,165
| New | +$328K |
|
|
BFIN
2166
DELISTED
BankFinancial
BFIN
| $328K | ﹤0.01% |
31,622
-900
| -3% | -$9.76K |
|
2167
Great Elm Capital Corp
GECC
$82.5M
| $328K | ﹤0.01% |
22,319
-9,241
| -29% | -$157K |
|
2168
Hippo Holdings
HIPO
$887M
| $328K | ﹤0.01% |
6,596
-15,077
| -70% | -$779K |
|
2169
OP Bancorp
OPBK
$228M
| $328K | ﹤0.01% |
23,706
| – | – |
|
2170
Harvard Bioscience
HBIO
$34.5M
| $327K | ﹤0.01% |
5,269
-8,437
| -62% | -$499K |
|
|
OPI
2171
DELISTED
Office Properties Income Trust
OPI
| $327K | ﹤0.01% |
+12,715
| New | +$323K |
|
2172
Teekay
TK
$1.17B
| $326K | ﹤0.01% |
102,947
-7,563
| -7% | -$24.5K |
|
|
CMBM
2173
DELISTED
Cambium Networks
CMBM
| $323K | ﹤0.01% |
13,643
-70,363
| -84% | -$1.7M |
|
2174
Bank First Corp
BFC
$1.7B
| $322K | ﹤0.01% |
4,477
+300
| +7% | +$21.4K |
|
2175
Rekor Systems
REKR
$80.3M
| $321K | ﹤0.01% |
70,300
-107,271
| -60% | -$505K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.